ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/anti-TIM3-monoclonal-antibody
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/anti-TIM3-monoclonal-antibody
3
trial(s) found.
ACTRN12621001265864
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine (
AMLM26-T5
)
DNA methyltransferase inhibitor
anti-TIM3 monoclonal antibody
antimetabolite
Acute myeloid leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05909904
Advanced
Phase 2
Active not recruiting
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (
BGB-HNSCC-201
)
anti-PD-1 monoclonal antibody
+ anti-TIM3 monoclonal antibody
Head and neck cancer
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Gold Coast Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05201066
Haem
Phase 2
Active not recruiting
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. (
CMBG453B12206B
)
anti-TIM3 monoclonal antibody
Leukaemia
Myelodysplastic syndrome
VIC
3168 - Clayton - Monash Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Active not recruiting (2)
Recruiting (1)
Recruitment Country and State
VIC (3)
QLD (2)
NSW (1)
SA (1)
WA (1)
Phase
Phase 1 / Phase 2 (1)
Phase 2 (2)
Trial Type
Haem (2)
Advanced (1)
Cancer Therapy Class
TIM3
100%
DNA methyltransferase
67%
PD-1
67%
PD-1/PD-L1
67%
LAG3
33%
BCL2
33%
Facility
3168 - Clayton - Monash Medical Centre (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
4215 - Southport - Gold Coast Private Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Acute myeloid leukaemia
Myeloid leukaemia
Head and neck cancer
Head and neck squamous cell carcinoma
Solid tumour
Myelodysplastic syndrome
Myeloproliferative neoplasm
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy